Locations:
SearchMolecular pathologist shares adenocarcinoma case
In this video, Jordan Reynolds, MD, anatomic and molecular pathologist at Cleveland Clinic’s Robert J. Tomsich Pathology and Laboratory Medicine Institute, discusses how fluorescence in situ hybridization testing ultimately gave a patient with adenocarcinoma options for less toxic chemotherapy.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Dr. Reynolds begins this three-minute video with an analysis of a slide obtained from an endobronchial ultrasound-guided fine needle aspiration. Watch as he demonstrates the diagnosis of lung cancer from small specimens:
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients